1. Home
  2. ORLA vs APGE Comparison

ORLA vs APGE Comparison

Compare ORLA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orla Mining Ltd.

ORLA

Orla Mining Ltd.

HOLD

Current Price

$14.49

Market Cap

4.5B

ML Signal

HOLD

Logo Apogee Therapeutics Inc.

APGE

Apogee Therapeutics Inc.

HOLD

Current Price

$78.09

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORLA
APGE
Founded
2007
2022
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.7B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ORLA
APGE
Price
$14.49
$78.09
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$27.00
$99.44
AVG Volume (30 Days)
3.5M
945.9K
Earning Date
11-11-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
2239.45
N/A
EPS
0.16
N/A
Revenue
$772,153,000.00
N/A
Revenue This Year
$183.80
N/A
Revenue Next Year
$36.88
N/A
P/E Ratio
$89.40
N/A
Revenue Growth
145.83
N/A
52 Week Low
$5.25
$26.20
52 Week High
$14.65
$80.99

Technical Indicators

Market Signals
Indicator
ORLA
APGE
Relative Strength Index (RSI) 66.36 68.95
Support Level $11.99 $73.55
Resistance Level $14.65 $80.99
Average True Range (ATR) 0.71 3.42
MACD 0.08 -0.36
Stochastic Oscillator 83.39 75.48

Price Performance

Historical Comparison
ORLA
APGE

About ORLA Orla Mining Ltd.

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Share on Social Networks: